- Home
- AKRO
as 12-18-2024 10:30am EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.2B | IPO Year: | 2019 |
| Target Price: | $46.83 | AVG Volume (30 days): | 535.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.32 - $37.00 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| White William Richard | AKRO | Chief Financial Officer | Dec 10 '24 | Sell | $30.79 | 2,817 | $86,735.43 | 38,335 | |
| Yale Catriona | AKRO | Chief Development Officer | Dec 10 '24 | Sell | $30.79 | 2,810 | $86,519.90 | 71,348 | |
| Young Jonathan | AKRO | Chief Operating Officer | Dec 10 '24 | Sell | $30.79 | 2,503 | $77,067.37 | 203,783 | |
| Cheng Andrew | AKRO | President and CEO | Dec 10 '24 | Sell | $30.79 | 7,855 | $241,855.45 | 597,562 | |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | Dec 10 '24 | Sell | $30.79 | 925 | $28,480.75 | 17,858 | |
| Young Jonathan | AKRO | Chief Operating Officer | Dec 2 '24 | Sell | $32.13 | 10,000 | $321,310.00 | 203,783 | |
| Cheng Andrew | AKRO | President and CEO | Dec 2 '24 | Sell | $32.09 | 25,000 | $802,250.00 | 597,562 | |
| Yale Catriona | AKRO | Chief Development Officer | Nov 15 '24 | Sell | $28.26 | 9,061 | $251,274.03 | 71,348 | |
| Yale Catriona | AKRO | Chief Development Officer | Nov 6 '24 | Sell | $35.19 | 10,000 | $351,890.00 | 71,348 | |
| Young Jonathan | AKRO | Chief Operating Officer | Nov 1 '24 | Sell | $32.15 | 50,716 | $1,601,251.55 | 203,783 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
Insider Monkey
14 days ago
Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
GlobeNewswire
22 days ago
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
MT Newswires
a month ago
Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target
GlobeNewswire
a month ago
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
GlobeNewswire
a month ago
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
TipRanks
a month ago
Akero Therapeutics Advances in MASH Treatment Trials
MT Newswires
a month ago
Akero Therapeutics' Q3 Net Loss Widens
GlobeNewswire
a month ago
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.